Fulvestrant for untreated hormone-receptor positive locally advanced metastatic breast cancer

The company’s submission (CS) reflects the scope of the appraisal issued by the National Institute for Health and Care Excellence (NICE). The submission assesses the clinical effectiveness and cost effectiveness of fulvestrant for untreated hormone-receptor positive locally advanced or metastatic breast cancer in comparison to aromatase inhibitors (AIs) (anastrozole and letrozole) or, when these are not tolerated or are contraindicated, tamoxifen.